NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma

CompletedPhase 2

Sponsor: Klaus Herfarth, MD

Conditions: Lymphoma, Malignant

Interventions: Rituximab

Countries: Germany

Combination of involved field radiotherapy for the control of macroscopic disease and CD20 antibody Rituximab for the control of microscopic remainders in other regions in patients with early stage nodal follicular lymphoma /grade I or II). Evaluation of DFSl and toxicity.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* verified follicular lymphoma grade 1 or 2
* only nodal involvement (incl. Waldeyer) clinical stage I or II
* largest tumor ≤ 7 cm
* adequate bone marrow reserves

Exclusion Criteria:

* ECOG \>2
* Follicular lymphoma grade 3
* buky disease (\>7 cm)
* involvement of the spleen
* neoplasia in PMH (except: basalioma, spinalioma)
* Immunodeficiency syndromes, viral hepatitis, connective tissue disease
* severe psychiatric disease
* pregnancy or breast feeding
* known allergies against foreign proteins

Locations (17)

Berlin, Germany
Berlin, Germany
Berlin, Germany
Cologne, Germany
Dresden, Germany
Essen, Germany
Göttingen, Germany
Hanover, Germany
Heidelberg, Germany
Kiel, Germany
Mainz, Germany
Mannheim, Germany
Marburg, Germany
Munich, Germany
Munich, Germany
Münster, Germany
Ulm, Germany